Proactive Investors - Run By Investors For Investors

Arix Biosciences boost after investee company floats on NASDAQ

The UK investor in life sciences opportunities owns a stake 12.9% stake in LogicBio
human genome
The US research and development group has licensed technology from Stanford and Texas universities that allows the insertion of corrective genes to the human genome

Arix Biosciences PLC (LON:ARIX) has seen a significant uplift in the value of its investment in a pre-clinical genome editing company, which recently made its stock market debut on NASDAQ.

The UK investor in life sciences opportunities owns a stake 12.9% stake in LogicBio (NASDAQ:LOGC), worth US$30mln, which is US$16mln more than Arix ploughed into the business.

READ: Arix Bioscience pours another £5.4mln into LogicBio as investee company lists on Nasdaq

The IPO, meanwhile, brought in gross proceeds of US$80.5mln and valued LogicBio at just over US$200mln at US$10 a share.

Founded four years ago and based in Cambridge, Massachusetts, the research and development group has licensed technology from Stanford and Texas universities that allows the insertion of corrective genes to the human genome.

It’s hoped the advance will allow LogicBio to create treatments for rare diseases with the company focusing initially on liver disorders in children.

View full ARIX profile View Profile

Arix Bioscience PLC Timeline

Related Articles

CBD oil
November 15 2018
The company’s technology creates nano-scale emulsion mixtures that allow fluids to mix that normally don’t mix, such as CBD oil and water
harley street
May 10 2019
Work at Advanced Onco’s Harley Street facility is due to complete within the next few months, and the first patient treated by LIGHT is slated for the second half of 2020
An illustration of Ozop's BLIF technique
March 30 2019
A key area of focus for the West Palm Beach, Florida, company is development of balloon lumbar interbody fusion (BLIF) technology

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use